Eighty-five percent or CHF 98 billion of chemical & pharmaceutical exports are contributed by the life sciences subsector, and more than a third of exports from this subsector are derived from so-called biopharmaceutical products (e.g., monoclonal antibodies).
Industrial white biotechnology shows major business potential, and bio-technological processes offer methods of sustainable manufacturing which are presently not being exploited optimally. Biosynthesis will become the “archetypal” manufacturing process for many organic chemicals, and biotransformation remains key to the specific functionalization of this process.
New value chains and microbial production methods will emerge based on rational metabolic and cellular engineering and will culminate in synthetic microbial life – a development that will open exciting new business opportunities.
Switzerland should capitalize on the success of red biotechnology (biopharmaceuticals) and establish a strong and well-connected industrial biotechnology community with a clear vision regarding areas of interest, strategic research and education agendas and an action plan.
Success is a question of “brains” and not of raw materials or infrastructure. However, the Swiss industrial biotech sector must be consolidated. The focus should be on products that are relevant for the Swiss economic space, such as small molecule pharmaceuticals, intermediates, fine chemicals, biochemicals and other specialties.
Similar to the biopharmaceuticals sector, the industrial biotech sector should become a similar or perhaps even larger contributor to the Swiss gross national product in the long term. The life science markets represent the key markets to be addressed, and the specific industries that should be addressed are those of organic chemicals, flavor and fragrances, cosmetics, dietary supplements, and feed and food, as well as other related industries. However, other markets and products must also be included, such as the biopolymers of MedTech, just to mention an example.
The scope of this joint Swiss Biotech Association & Swiss Academy of Engineering Sciences activity will be narrowed down to specific products and industrial processes using the suspension culture of prokaryotic and eukaryotic cells. Agricultural production methods, including PMP (plant-made pharmaceuticals), are not within the scope of this study.
Additionally, the biobased economy and the circular economy are not the primary subjects of this investigation, although they are connected. However, we will coordinate with those bodies (e.g., SKB and science-industries) to contribute to our collected data, targeting these topics specifically.
The following agenda will be pursued to recognize and realize the value of industrial biotech (IB) for the Swiss economy: